At Advanced Accelerator Applications, we are reimagining nuclear medicine and cancer care. Our mission is to transform patients’ lives by developing and delivering targeted radioligand therapies and …

In August 2024, Siemens Healthineers bought the diagnostic arm of Advanced Accelerator Applications that specialises in producing radioactive chemicals used for cancer scan for more than $224 million.

Siemens Healthineers has concluded the acquisition from Novartis of Advanced Accelerator Applications Molecular Imaging, a European manufacturing and distribution network of diagnostic …

Our core mission is to develop, manufacture, test, and timely supply radiopharmaceutical products for patients in need, with a primary focus on oncology, while expanding our network and expertise...

Oct 30, 2017 · Advanced Accelerator Applications (NASDAQ: AAAP) is a radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicines including Lutathera ® …

Advanced Accelerator Applications (NASDAQ: AAAP), a Novartis company, is an innovative radiopharmaceutical company developing, producing and commercializing molecular nuclear …

Jun 24, 2025 · Advanced Accelerator Applications, a Novartis company, (acquired for $3.9B in October 2017) develops, manufactures and markets radiopharmaceuticals for diagnostic and therapeutic …